PARLIAMENTARY WRITTEN QUESTION
Prostate Cancer: Screening (5 November 2024)

Screening for prostate cancer is currently not recommended by the UK National Screening Committees (UK NSC). This is because of the inaccuracy of the current best test, called the Prostate Specific Antigen (PSA). A PSA-based screening programme could harm some men as many would be diagnosed with a cancer that would not have caused them problems during their life. This would lead to additional tests and treatments which can also have harmful side effects, such as sexual dysfunction and incontinence.

The UK NSC regularly reviews its recommendations, and the evidence review for prostate cancer screening is underway and plans to report within the UK NSC’s three-year work plan.

The evidence review includes modelling the clinical effectiveness and cost of several approaches to prostate cancer screening, including different potential ways of screening the whole population from 40 years of age onwards, and targeted screening aimed at groups of people identified as being at higher than average risk, such as black men or men with a family history of cancer.